A useful exercise when reading the current psychedelic regulatory moment is to lay out the actual chronology of FDA actions on psychedelic programs over the past decade. The press coverage tends to focus on individual events as discrete signals: the 2017 MDMA breakthrough, the 2024 advisory committee vote, the 2026 executive order. Read in isolation, each can be made to support whatever narrative the reader wants to construct.
Read in sequence, the picture is different. The agency’s posture across nine years has been consistent on the methodological questions that matter, even as the political environment around the agency has shifted dramatically. The Lykos rejection in 2024 was not an aberration; it was the predictable outcome of a decade-long pattern. The 2026 voucher decisions are not a reversal of that pattern; they are the same agency applying the same standards to programs that met them.
This is a reference timeline of the FDA’s engagement with psychedelic programs from 2017 through May 2026. It is intended as a citable reference for any subsequent piece that wants to anchor claims about the regulatory history in dated facts.
August 2017: MDMA receives Breakthrough Therapy designation
The FDA granted Breakthrough Therapy designation to MDMA-assisted therapy for PTSD, with the Multidisciplinary Association for Psychedelic Studies (MAPS) as sponsor through its for-profit subsidiary MAPS Public Benefit Corporation. The designation was significant for two reasons. First, it was the first formal regulatory recognition that a classical psychedelic could meet the substantial-improvement standard the Breakthrough designation requires. Second, it triggered the structured Phase 3 development program that would eventually produce the trials submitted for approval seven years later.
The designation also produced the first round of FDA methodological guidance on the program, in the form of an agreed Special Protocol Assessment for the Phase 3 trials. The SPA addressed trial design, endpoints, and the use of psychotherapy as an integrated component of the drug intervention. The methodological challenges that would later define the program’s regulatory difficulty (functional unblinding, integration therapy standardization, safety reporting) were already identified in the SPA discussions. They were not new findings in 2024. They were known concerns from 2017 forward.
October 2018: Psilocybin receives Breakthrough Therapy designation for treatment-resistant depression
Compass Pathways received Breakthrough Therapy designation for COMP360 in October 2018. The designation came two years before the company’s Phase 2b readout, on the strength of preliminary clinical evidence and the unmet-need argument in TRD. Compass’s commercial structure (a publicly traded biotech focused on a single asset and indication) was a deliberate contrast to MAPS’s nonprofit-with-PBC model. The two approaches to psychedelic development were now formally recognized by the agency as different operating tracks within a shared regulatory framework.
2019: Usona receives Breakthrough Therapy designation for major depressive disorder
The Usona Institute, a nonprofit pharmaceutical research organization, received Breakthrough Therapy designation for synthetic psilocybin in major depressive disorder in 2019. This was the third Breakthrough designation in the psychedelic space and the second psilocybin program. The three breakthrough programs by 2019 (MDMA, Compass psilocybin, Usona psilocybin) established that the agency was prepared to engage with psychedelics as a class while preserving its standards for the underlying evidence.
March 2019: Esketamine (Spravato) approved for TRD
This is the most consequential event in the psychedelic regulatory history that the field tends not to discuss as such. Esketamine, an NMDA receptor antagonist with dissociative and hallucinogenic effects, was approved by the FDA in March 2019 for treatment-resistant depression. It is a Schedule III controlled substance with REMS-controlled administration: dosing in certified healthcare settings, two-hour observation after each dose, no take-home use. The framework the FDA constructed for esketamine in 2019 became, in effect, the template for how the agency would approach any future psychedelic approval.
For sponsors of classical psychedelic programs, esketamine’s approval was both a positive signal and a methodological reference. Positive because it demonstrated the agency would approve a centrally acting, dissociation-producing compound for psychiatric indication. Methodological because the REMS framework esketamine launched under indicated what the agency would require for any subsequent compound in the same general regulatory class.
June 2023: FDA publishes draft guidance on clinical trials with psychedelic drugs
This was the first formal FDA guidance document specifically addressing psychedelic clinical trials. The document covered trial design considerations, dosing site requirements, expectancy and blinding concerns, the role of psychotherapy components, and safety monitoring expectations. The comment period closed on August 25, 2023.
The guidance was draft and remained so for nearly three years. Throughout that period, sponsors operated under its framework while continuing to engage the agency on case-by-case program questions. The document’s methodological commitments were consistent with the regulatory positions the agency had taken in individual program interactions since 2017; it formalized what had already been signaled.
The April 2026 FDA announcement that the guidance would be finalized “imminently” means the document the field has been operating under in draft form for nearly three years is about to become the formal regulatory framework. The shift from draft to final is not a substantive policy change; it is a procedural step that codifies positions the agency has been holding for years.
August 2023: MAPS Phase 3 MAPP2 results published
The second confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD (MAPP2) published its primary results in Nature Medicine. The trial met its primary endpoint with statistical significance. Combined with the earlier MAPP1 trial, the program now had two positive Phase 3 trials supporting the eventual NDA submission. The press coverage at the time framed this as a near-certain path to approval.
February 2024: MAPS rebrands to Lykos Therapeutics
The for-profit subsidiary MAPS Public Benefit Corporation rebranded to Lykos Therapeutics in early 2024, restructuring its commercial team and preparing for the expected commercial launch following anticipated FDA approval. The rebranding decoupled the commercial entity from the nonprofit MAPS legacy in preparation for what the company expected to be a market launch.
June 4, 2024: PDAC advisory committee meeting
The FDA’s Psychopharmacologic Drugs Advisory Committee met to review the Lykos MDMA-assisted therapy NDA. The committee voted 9-2 against the question of whether the available data show that the drug is effective in patients with PTSD, and 10-1 against the question of whether the benefits of the drug outweigh its risks.
The committee’s discussion centered on functional unblinding, the lack of standardization in the psychotherapy component, safety reporting concerns (including the documented instructions to trial sites not to record certain euphoria-related effects as adverse events), the influence of prior MDMA use among participants on the trial results, and durability of benefit questions. Each of these concerns had been documented in FDA communications throughout the development cycle. None were new in June 2024.
August 9, 2024: FDA issues Complete Response Letter to Lykos
The FDA rejected the Lykos NDA, requesting an additional Phase 3 trial to address the methodological concerns identified in the advisory committee discussion. The CRL was issued approximately two months after the advisory committee vote.
August 15, 2024: Lykos announces 75% workforce reduction
Lykos publicly announced the layoff of approximately 75 percent of its workforce (approximately 75 of 100 employees) in the week following the CRL. Founder Rick Doblin departed the company’s board. CEO Amy Emerson stepped down in September 2024.
September 4, 2025: FDA publishes the Lykos CRL
As part of a broader release of 89 previously unpublished Complete Response Letters, the FDA made public the full redacted text of the Lykos CRL. The document is now publicly readable and represents the most detailed regulatory document on any psychedelic program in the agency’s history. The methodological concerns it documents are sufficiently specific that any subsequent psychedelic sponsor can use it as a reference for what the agency considers binding and what it considers negotiable.
August 2025: Lykos rebrands to Resilient Pharmaceuticals
The company changed its name to Resilient Pharmaceuticals, signaling a strategic repositioning. The company stated its intent to engage with the FDA on a path forward for the MDMA program. As of mid-2026, the company has not, by available reporting, launched the additional Phase 3 trial the original CRL requested.
February 4, 2026: Compass announces positive COMP006 Phase 3 results
Compass Pathways announced positive topline results from COMP006, the second of its two pivotal Phase 3 trials of COMP360 in treatment-resistant depression. Combined with the COMP005 results from June 2025, the program now had two positive Phase 3 trials and was positioned for NDA submission.
February 2026: Transcend publishes IMPACT-1 Phase 2 results
Transcend Therapeutics’ Phase 2 trial of methylone (TSND-201) in PTSD published in JAMA Psychiatry. The trial met its primary endpoint. The trial design, with a placebo control and four weekly dosing sessions, generated data that the agency would later signal it considered methodologically interpretable.
April 18, 2026: Trump executive order on psychedelics
President Trump signed Executive Order 14318, Accelerating Medical Treatments for Serious Mental Illness, directing the FDA Commissioner to provide Commissioner’s National Priority Vouchers to psychedelic drugs with Breakthrough Therapy designations meeting the program’s criteria. The order also directed FDA and DEA to establish a Right to Try pathway for ibogaine compounds, and allocated $50 million in ARPA-H funding for federal-state collaboration on psychedelic research.
April 23, 2026: DOJ cannabis schedule III final order
Five days after the psychedelic executive order, the Department of Justice issued a final order rescheduling FDA-approved cannabis drug products and state-licensed medical marijuana from Schedule I to Schedule III. The cannabis order is a separate regulatory action but is relevant to the psychedelic timeline because it signals an administration posture that is willing to move on controlled-substance scheduling decisions, which has historical implications for any future psychedelic rescheduling consideration.
April 24, 2026: FDA issues first psychedelic priority vouchers
The FDA awarded Commissioner’s National Priority Vouchers to three programs: Compass Pathways’ COMP360, the Usona Institute’s PSIL201, and Transcend Therapeutics’ TSND-201 (with Otsuka Pharmaceutical acquiring Transcend for $1.225 billion the same week). Compass also received approval for a rolling NDA submission and review. The FDA stated that final guidance for sponsors developing psychedelic drugs would be released “imminently.”
Resilient Pharmaceuticals was eligible for but not selected for a voucher.
The pattern
Reading the timeline as a whole, three things stand out.
First, the FDA’s methodological positions have been consistent since 2017. Functional unblinding, expectancy effects, psychotherapy standardization, safety reporting integrity, durability of benefit, trial population representativeness: these concerns appear in agency communications from the 2017 SPA discussions onward. The Lykos rejection in 2024 enforced positions the agency had stated for seven years. The voucher selections in 2026 reflected the same positions applied to programs that had built methodologically defensible cases. The pattern is one continuous posture across multiple administrations, multiple commissioners, and multiple political environments.
Second, the political environment has shifted substantially without the methodological posture shifting with it. The 2017 breakthroughs came during the first Trump administration. The 2023 draft guidance came during the Biden administration. The 2024 Lykos CRL came during the Biden administration. The 2026 executive order and the voucher selections came during the second Trump administration. The agency’s posture on the underlying methodological questions has been functionally identical across all of these periods. The political ground moves; the standards do not.
Third, the timeline contains exactly one regulatory rejection of a psychedelic program (Lykos, August 2024) and one approval-pathway commitment with rolling review (Compass, April 2026). Between these two events, the field has produced ten Phase 3 trial readouts across multiple programs. The pattern is selective acceleration, not blanket endorsement. The agency continues to distinguish between programs whose methods it considers defensible and programs whose methods it does not.
Read against this timeline, the current voucher moment is less surprising and more legible. The agency is doing what it has done for nine years. It is accelerating programs that have built methodologically defensible cases for their indications. It is not accelerating programs that have not. The political weather is a permission structure for speed within the methodological set; it has not changed the set.
For sponsors planning programs in the next phase of the field, the operational lesson is that what the FDA does is more predictable than what the press coverage of FDA actions suggests. The agency tells sponsors what it cares about, and tells them repeatedly. Programs that listen to that signal and build their methodological cases around it tend to get acceleration when the political environment opens up to it. Programs that treat the agency’s stated concerns as administrative noise tend to discover, eventually, that they were not.
The next inflection point on this timeline is the FDA’s finalization of the 2023 draft guidance. Behavioral Wire will be tracking it as it lands.